Virpax Pharmaceuticals

Virpax Pharmaceuticals Announces Positive Results in Study for Long-Lasting Pain Relief Formulation

BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has reported encouraging results from a minipig Dose Range Finding (DRF) study for Probudur, its long-acting liposomal bupivacaine injection. Designed to provide …

Virpax Pharmaceuticals Announces Positive Results in Study for Long-Lasting Pain Relief Formulation Read More

Virpax Pharmaceuticals

Virpax Pharmaceuticals Extends Collaboration with NIH Center for Pain Management Innovation

BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), a division …

Virpax Pharmaceuticals Extends Collaboration with NIH Center for Pain Management Innovation Read More

Trevena

Revolutionary Preclinical Data Unveiled by Trevena: Potential New Direction in Neuropathic Pain and Acute Seizure Management

CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), announced key data today from two separate preclinical studies. The data provides fascinating insights into the potential effects of TRV045, a novel S1P1 …

Revolutionary Preclinical Data Unveiled by Trevena: Potential New Direction in Neuropathic Pain and Acute Seizure Management Read More